John Carethers | DNA Repair | Best Researcher Award

Published on by Cell Biologist

Prof. John Carethers | DNA Repair | Best Researcher Award

Prof. John Carethers, UC San Diego, United States

Dr. John M. Carethers is a distinguished academic leader and physician-scientist in the field of gastroenterology and cancer genetics. Serving as Vice Chancellor for Health Sciences at the University of California San Diego, he also holds professorial appointments in both the School of Medicine and the Herbert Wertheim School of Public Health. His extensive contributions to colorectal cancer research, health disparities, and tumor biology have earned him national recognition. Dr. Carethers is renowned for his work on DNA mismatch repair mechanisms and their implications in cancer progression and treatment responsiveness. With a prolific publication record and influential roles in medicine and science policy, he stands as a model for translational research excellence. His commitment to mentorship and health equity further underscores his holistic impact on the field of medicine. Dr. Carethers continues to push scientific boundaries while advocating for inclusive healthcare solutions.

Publication Profile: 

Google Scholar

Scopus

Education:

Dr. Carethers completed his undergraduate education at Wayne State University, earning a B.S. in Biological Sciences with a minor in Chemistry (1981–1985). He graduated with distinction and was a recipient of the Michigan State Competitive Scholarship. He continued at Wayne State University School of Medicine, where he earned his M.D. with High Distinction in 1989. His academic performance was recognized with multiple honors including the Dean’s Academic Achievement Award and awards from the Black Medical Association. Dr. Carethers then completed an internship in Internal Medicine at Massachusetts General Hospital (1989–1990), a prestigious Harvard-affiliated institution, under the guidance of Chief of Medicine Dr. John T. Potts. His medical and research training provided the foundation for a career focused on gastrointestinal disorders, tumor genetics, and health disparities, particularly in colorectal cancer. His formative years reflect academic excellence and an early commitment to advancing medicine through both practice and research.

Professional Experience:

Dr. John M. Carethers currently serves as the Vice Chancellor for Health Sciences at the University of California San Diego. He is also a Distinguished Professor in the Department of Medicine and an Adjunct Professor in the School of Public Health. His career has spanned prestigious academic roles, including clinical and research leadership in gastroenterology, particularly focused on colorectal cancer. A physician-scientist, Dr. Carethers has served in roles that bridge bench science and clinical application, contributing significantly to translational medicine. His academic journey includes mentorship of emerging scientists, leadership in national research initiatives, and board participation in scientific organizations. His experience also encompasses major roles in cancer health disparities research, aiming to close gaps in outcomes across racial and socioeconomic lines. Dr. Carethers is a prolific researcher and thought leader whose experience enhances institutional vision, diversity, and health equity. His impactful career exemplifies a dedication to excellence in science and medicine.

Awards and Honors:

Dr. Carethers has been recognized with numerous academic and professional honors throughout his career. As an undergraduate, he received the Michigan State Competitive Scholarship and was inducted into the Golden Key National Honor Society. During medical school, he earned the Dean’s Academic Achievement Award and awards from the Black Medical Association in 1986 and 1987. Over time, he has been widely honored for his contributions to colorectal cancer research, healthcare leadership, and advocacy for health equity. His published work has been highly cited and influential in advancing our understanding of tumor genetics and mismatch repair. He has received numerous invitations for keynote talks and appointments to national research boards and committees. Dr. Carethers’s career has been marked by his commitment to mentoring, scholarly productivity, and advocacy, positioning him as a leader and role model in academic medicine. These honors underscore his national and global influence in health sciences.

Research Focus:

Dr. John M. Carethers’s research primarily focuses on colorectal cancer, particularly mechanisms of tumor progression, genetic and epigenetic alterations, and mismatch repair (MMR) deficiency. He has deeply explored how MMR status influences treatment responses, especially to chemotherapy agents like 5-fluorouracil. A key aspect of his work includes identifying biomarkers for cancer prognosis and understanding familial cancer syndromes, including Lynch syndrome and polyposis syndromes. His studies also delve into the molecular mechanisms underlying microsatellite instability (MSI) and its role in genomic instability. Importantly, Dr. Carethers is a leading voice in cancer health disparities, examining how social, economic, and biological factors impact outcomes among underrepresented populations. His research bridges basic molecular science with clinical applications, enabling personalized approaches to treatment and surveillance. Through his work, he contributes to reducing cancer burden and mortality while promoting health equity in vulnerable communities—making him a pioneer in both biomedical research and public health.

Publications Top Notes:

  1.  Experimental and clinical observations on frostbite

  2.  The epidemiology of methicillin-resistant Staphylococcus aureus in a burn center

  3.  Extraintestinal Manifestations of Crohn’s Disease

  4.  Human chromosome 3 corrects mismatch repair deficiency in colon tumor cells

  5.  Delayed gastric emptying after laparoscopic vagotomy

  6.  Mismatch repair and the G2 cell cycle checkpoint

  7. In vitro assay for screening hMLH1 and hMSH2 mutations

  8.  Massive secretory diarrhea and pseudo-obstruction in Crohn’s disease

  9.  Mismatch repair blocks clonal expansion after DNA damage

  10.  Localization of Bannayan-Riley-Ruvalcaba syndrome gene to chromosome 10q23

Conclusion:

In conclusion, Dr. John M. Carethers embodies the highest standards of research excellence, leadership, and societal impact. His contributions to colorectal cancer genetics, DNA mismatch repair research, and cancer health disparities are not only scientifically rigorous but also clinically transformative. As a widely respected physician-scientist, educator, and health equity advocate, he represents the ideal blend of scholarly productivity and service to humanity. Despite minor opportunities for expanding the global and technological dimensions of his work, Dr. Carethers’s achievements place him in the top tier of biomedical researchers. His continued dedication to both advancing science and closing health outcome gaps aligns perfectly with the spirit of the Best Researcher Award. He is not only deserving of this honor but also serves as an inspiring model for current and future generations of researchers.

Hannah Wen | Breast Cancer | Best Researcher Award

Published on by Cell Biologist

Dr. Hannah Wen | Breast Cancer | Best Researcher Award

Dr. Hannah Wen, MEMORIAL SLOAN KETTERING CANCER CENTER, United States

Dr. Hannah Y. Wen, M.D., Ph.D., is a distinguished breast cancer pathologist and cancer researcher at Memorial Sloan Kettering Cancer Center (MSKCC) in New York. With dual training in medicine and cancer biology, Dr. Wen’s career reflects a deep commitment to advancing the field of translational oncology. Her research focuses on triple-negative breast cancer (TNBC), rare breast tumor subtypes, and predictive/prognostic biomarkers. Dr. Wen is a prolific academic contributor with publications in high-impact journals such as Nature Communications and Cancer Research. She integrates molecular biology with diagnostic pathology to improve cancer stratification and therapy decisions. In addition to her investigative work, she contributes as a principal investigator on multiple IRB-approved studies at MSKCC. Recognized with early academic accolades and continuously advancing the frontiers of cancer pathology, Dr. Wen exemplifies the blend of scientific rigor and clinical relevance. She is a strong candidate for any prestigious research award in pathology and oncology.

Publication Profile:

Scopus

Strengths for the Award:

  1. Extensive Academic Training
    Dr. Wen holds an M.D. from Peking University Health Science Center, one of China’s top medical schools, and a Ph.D. in Cancer Biology from MD Anderson Cancer Center, a global leader in cancer research.

  2. Robust Postdoctoral and Clinical Research Experience
    Her postdoctoral work at Genentech Inc. and ongoing clinical-scientific role at Memorial Sloan Kettering Cancer Center (MSKCC) place her at the intersection of innovative molecular research and high-impact clinical diagnostics.

  3. High-Impact Publications
    She has authored landmark papers in journals like Cancer Research, Nature Cell Biology, PNAS, Modern Pathology, and Nature Communications, covering diverse areas such as:

    • Triple-negative breast cancer

    • Genetic markers (e.g., BRCA1, p202)

    • Molecular subtyping of rare breast tumors

    • Pathologic stratification of early-stage breast cancer

  4. Active Investigator and IRB Leadership
    Dr. Wen is Principal Investigator for multiple MSK IRB protocols involving rare breast cancer subtypes and molecular markers. This shows strong leadership in translational research.

  5. Recognition and Consistency
    From receiving Top 10 Student Awards in Beijing to leading diagnostic-pathologic breakthroughs in 2025, her excellence spans over three decades.

Areas for Improvement:

  1. Visibility of Awards in the U.S. Academic System
    While her early academic awards are impressive, more documented recent honors, society memberships, or fellowships could further enhance her candidacy.

  2. Mentorship and Teaching Roles
    While likely involved, specific mention of mentorship, educational leadership, or curriculum development would strengthen her profile in academic impact.

  3. Interdisciplinary Collaborations
    Explicit examples of cross-disciplinary collaborations (e.g., computational oncology, AI in pathology) would underscore her innovation potential in modern biomedical research.

Education:

Dr. Hannah Y. Wen obtained her M.D. from Peking University Health Science Center, Beijing, China (1988–1993), where she was consistently recognized as an outstanding student. She pursued her Ph.D. in Cancer Biology at the University of Texas Health Science Center/MD Anderson Cancer Center in Houston, TX (1997–2001), focusing on molecular oncology. During her Ph.D., she contributed significantly to understanding interferon-inducible proteins in cancer suppression. Her educational journey reflects deep interdisciplinary training, combining clinical medicine with cutting-edge research. This robust academic background has laid the foundation for her success in translational cancer research and diagnostic pathology. Dr. Wen’s training continues with postdoctoral work at Genentech Inc. in Experimental Pathology, which further honed her molecular diagnostic skills. Her global academic trajectory—from China to elite U.S. institutions—has shaped her into a well-rounded researcher capable of addressing complex challenges in breast cancer diagnosis and treatment.

Experience:

Dr. Wen brings over two decades of research and clinical experience in cancer biology and diagnostic pathology. After completing her Ph.D. at MD Anderson Cancer Center, she conducted postdoctoral research in Experimental Pathology at Genentech, Inc., South San Francisco (2002–2003). Since then, she has held a faculty position at the Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center. At MSKCC, Dr. Wen has served as Principal Investigator on multiple IRB-approved protocols investigating rare breast cancer subtypes and genetic alterations. Her daily work bridges histopathology and genomics to advance precision medicine in breast cancer. Beyond research, she mentors fellows and contributes to academic committees, reinforcing her role as a leader in her field. Her hands-on experience with triple-negative breast cancer, breast tumor markers, and breast pathology variants gives her a rare clinical-research dual expertise, making her a vital figure in contemporary breast cancer diagnostics.

Awards and Honors:

Dr. Hannah Y. Wen has received numerous recognitions throughout her academic journey. Early in her career, she was honored with the Outstanding Student Award by Peking University Health Science Center (1988–1992), a distinction granted to top-tier medical students. She was also named among Beijing’s Top 10 Outstanding Students in 1992, recognizing her academic and leadership excellence. While formal awards during her U.S. career are not extensively documented in the data provided, Dr. Wen’s growing impact in high-impact journals and role as a Principal Investigator at MSKCC are implicit accolades in the competitive world of academic medicine. Her contributions to translational breast cancer research, including studies on BRCA1 inactivation and tumor progression markers, underscore her continuous excellence. Given her record of impactful research and professional standing at one of the world’s leading cancer centers, she remains a strong contender for recognition such as the Best Researcher Award.

Research Focus:

Dr. Wen’s research centers on triple-negative breast cancer (TNBC), a challenging and aggressive subtype of breast cancer with limited therapeutic targets. She also investigates rare and under-recognized breast tumor subtypes such as microglandular adenosis, acinic cell carcinoma, and tall cell carcinoma with reversed polarity. Her work involves the identification of predictive and prognostic markers, employing techniques such as targeted gene sequencing, BRCA1 methylation analysis, and molecular stratification models. As Principal Investigator, she leads studies under MSK IRB Protocols #16-411 and #16-596, exploring the genomic and epigenetic landscape of TNBC. Her research stands out for its clinical translation, directly impacting patient diagnosis and treatment planning. Recent contributions to Nature Communications and Modern Pathology show her innovative use of multimodal histopathological models and molecular profiling. Dr. Wen’s research reflects a powerful blend of diagnostic pathology, molecular genetics, and precision oncology—positioning her as a leader in breast cancer research.

Publications Top Notes:

  1.  The Role of Platelet Activating Factor in Reproduction – Progress of Anatomical Sciences (1996)

  2.  Transforming Growth Factor-α and Its Receptor in Reproduction – Medical Sciences (1997)

  3.  TGF-α Expression in Mouse Embryos and Uterus – J. Beijing Medical Univ. (1997)

  4.  p202 Slows Prostate Cancer Cell Growth – Oncogene (1999)

  5.  p202 Enhances TNF-α-Induced Apoptosis in Breast Cancer – Cancer Research (2000)

  6.  β-catenin as a Prognostic Marker in Breast Cancer – PNAS USA (2000)

  7.  HER-2/neu Drives Androgen-Independent Prostate Cancer – Cancer Research (2000)

  8.  EGFR’s Nuclear Role as a Transcription Factor – Nature Cell Biology (2001)

  9.  p202 Mediates Anti-Tumor Activity in Pancreatic Cancer – Cancer Research (2001)

  10.  Systemic Tumor Suppression via Bik Gene – Cancer Research (2002)

Conclusion:

Dr. Hannah Y. Wen is a highly qualified and deserving nominee for the Best Researcher Award. Her outstanding academic background, consistent and impactful research output, and leadership in breast cancer pathology make her a top-tier researcher in the field of translational oncology. She excels in integrating molecular biology with diagnostic pathology to improve cancer detection, stratification, and treatment.

With minor enhancements in visibility and cross-disciplinary leadership, Dr. Wen is not only suitable but a model candidate for this award. Her work is advancing breast cancer care at both the bench and bedside—fulfilling the core mission of research excellence.

Sophie Paczesny | Immunotherapy | Best Researcher Award

Published on by Cell Biologist

Prof. Sophie Paczesny | Immunotherapy | Best Researcher Award

Prof. Sophie Paczesny, Medical Univeristy of South Carolina, United States

Dr. Sophie Paczesny, M.D., Ph.D., is an internationally recognized leader in immunology and cancer research. Currently, she serves as Professor of Immunology & Pediatrics and the Sally Abney Rose Endowed Chair in Cancer Stem Cell Biology at the Medical University of South Carolina (MUSC). She is also Co-Leader of the Cancer Biology & Immunology Program at the Hollings Cancer Center. With a deep commitment to improving outcomes in hematopoietic cell transplantation, her translational research bridges clinical and laboratory advances in graft-versus-host disease (GVHD), biomarkers, and tumor immunology. Her work has shaped diagnostic and therapeutic strategies across pediatric and adult oncology. Dr. Paczesny’s pioneering studies on dendritic cell vaccines and immune reconstitution have led to impactful, high-citation publications in journals like Blood, JCI Insight, and Journal of Clinical Oncology. She continues to mentor the next generation of physician-scientists while advancing cutting-edge immune-oncology research globally.

Publication Profile: 

Orcid

Scopus

✅ Strengths for the Award:

  1. Pioneering Work in Immunology & Transplantation
    Dr. Paczesny has significantly advanced our understanding of graft-versus-host disease (GVHD) through the development of novel biomarkers, improving diagnostics, patient stratification, and therapeutic decisions in hematopoietic cell transplantation.

  2. High-Impact Publications
    With over 20 influential publications, including in Blood, JCI Insight, Journal of Clinical Oncology, and British Journal of Haematology, she has made consistent contributions to high-impact journals, underscoring the translational value of her work.

  3. Strong Interdisciplinary Background
    Her dual degrees (M.D., Ph.D.), combined with training across mathematics, life sciences, tumor immunology, and cell therapy, enable her to bridge basic science and clinical application effectively.

  4. Leadership and Mentorship
    Holding senior positions such as Professor, Endowed Chair, and Program Co-Leader at MUSC, she demonstrates strong leadership and commitment to fostering academic growth in immunology and pediatrics.

  5. Global and Collaborative Impact
    Her participation in international collaborations and consortia (e.g., Pediatric Transplant and Cellular Therapy Consortium) highlights her global influence and scientific diplomacy.

  6. Innovative Clinical Translation
    She led or contributed to the development of decision-support tools (e.g., biomarker-based decision trees for VOD/SOS), which have the potential to shift real-world clinical practices.

⚙️ Areas for Improvement:

  1. Outreach & Visibility
    Despite her extensive contributions, Dr. Paczesny may benefit from more frequent keynote talks, scientific media presence, or public engagement efforts to raise broader awareness of her work among policymakers, patients, and industry.

  2. Startup/Commercial Translation
    While highly research-driven, expanding into biotech or diagnostic tool commercialization could further translate her biomarker discoveries into scalable clinical solutions.

  3. Grant Leadership Details
    The provided information doesn’t detail the scope of grants led (e.g., NIH R01s, consortia P01s). Adding these details could strengthen evaluations by funding and award committees.

🎓 Education:

Dr. Paczesny began her academic journey in France, earning a B.S. in Mathematics and Life Sciences from the Academy of Nancy-Metz (1985–1989). She pursued her M.D. at the University of Strasbourg, completing her medical degree in 1995. Her passion for cellular therapies led her to obtain an M.S. in Cell Therapy and Biology of Hematopoietic Cells from the University of Paris VII in 1999. She continued her scientific training by earning a Ph.D. in Tumor Immunology at the same institution in 2004. Her educational background reflects a unique blend of clinical training and basic science, providing the foundation for her translational research in immunology and cancer biology. This multidisciplinary training has enabled her to tackle complex clinical problems like graft-versus-host disease and immune response modulation from both therapeutic and mechanistic angles.

🩺 Professional Experience:

Dr. Sophie Paczesny has held academic and clinical positions in both Europe and the United States. She began her faculty career as Assistant Professor of Pediatrics at the University and Hospitals of Nancy (2003–2005). She transitioned to the U.S. as Assistant Professor of Pediatrics and Communicable Diseases at the University of Michigan (2009–2012). From 2012–2015, she served as Associate Professor at Indiana University School of Medicine, holding appointments in Pediatrics, Microbiology, and Immunology. She also contributed to the Melvin and Bren Simon Cancer Center. Currently, she is a Professor at the Medical University of South Carolina (MUSC), where she leads research and training efforts in immunology and cancer biology. Across all roles, she has led NIH-funded programs, advanced biomarker research, mentored junior investigators, and contributed to the development of immunotherapeutic approaches in hematopoietic cell transplantation and cancer.

🏅 Honors and Awards:

Dr. Paczesny has received numerous honors recognizing her contributions to science and medicine. In 1999, she earned Second Prize at the Avicenne Hospital Research Meeting in Paris. In 2000, she was awarded the Médaille d’Argent (Silver Medal) from Paris University Hospitals’ residency program. That same year, she co-received First Prize for Best Fellow Academic Work in France, acknowledging her early excellence in clinical and research training. Her ongoing research has been consistently supported by competitive grants and featured in high-impact journals, highlighting her leadership in biomarker discovery and immune-oncology. As an endowed chair at MUSC and an invited speaker at leading international conferences, her work continues to gain recognition. These awards underscore both her clinical insight and scientific innovation, particularly in the fields of transplant immunology and cancer immunotherapy.

🔬 Research Focus:

Dr. Paczesny’s research is centered on translational immunology, with a special focus on graft-versus-host disease (GVHD), immune reconstitution, and cancer immunotherapy. She has pioneered the use of biomarkers to predict outcomes and complications in hematopoietic stem cell transplantation, including veno-occlusive disease and chronic GVHD. Her studies have uncovered novel immune pathways and prognostic indicators, many of which have informed clinical trials and therapeutic strategies. Additionally, she explores dendritic cell vaccines, immunopeptidomics, and HLA allele influences on transplant success. Her collaborative projects span pediatric and adult immunology, contributing to national consortia such as the Pediatric Transplant and Cellular Therapy Consortium. Her ultimate goal is to enhance survival while reducing toxicities of transplantation through immune-guided, precision medicine approaches. She is especially known for integrating advanced statistical modeling and immunobiology to address real-world clinical challenges.

📚 Publications Top Notes: 

  1. 🧫 Protection of mice against leukemia after vaccination with dendritic cells – Cancer Research (2001)

  2. 💉 Monoclonal anti-IL-6 antibody treatment in B-lymphoproliferative disorder – Blood (2001)

  3. 🧬 CD34+ dendritic cell vaccine induces T-cell immunity in melanoma – J Immunother (2003)

  4. 🦠 Dendritic cells as immune controllers and therapeutic tools – Ann NY Acad Sci (2003)

  5. 🎯 Dendritic cells as vectors for cancer immunotherapy – Semin Cancer Biol (2003)

  6. 🧪 Melanoma vaccines using dendritic cells – Dev Biol Basel (2004)

  7. 🧫 CD8+ T-cell expansion in melanoma patients post-vaccination – J Exp Med (2004)

  8. 🧾 Tumor inhibition assay for CTL response post-vaccine – J Immunother (2005)

  9. 🔁 Peptide-pulsed dendritic cells boost melanoma-specific CD8+ T cells – J Immunother (2005)

  10. 📈 Advances in dendritic cell-based immunotherapy – Adv Exp Med Biol (2005)

🧾 Conclusion:

Dr. Sophie Paczesny embodies the ideal recipient of the Best Researcher Award. She has made transformative contributions to immunology, stem cell biology, and cancer therapeutics, particularly in the field of biomarker-driven precision medicine. Her leadership in both academia and collaborative clinical research has shaped safer and more effective treatment strategies for transplant patients worldwide.

Her depth of expertise, sustained research output, and ongoing innovations place her at the forefront of translational immunology. While minor gains could be made in public visibility and translational enterprise, her impact on science and patient care is profound.

Zhijie Chang | Extracellular Vesicles | Cell Communication Award

Published on by Cell Biologist

Prof. Zhijie Chang | Extracellular Vesicles | Cell Communication Award

Prof. Zhijie Chang, Tsinghua University, China

Professor Zhijie Chang is a distinguished molecular biologist and tenured professor at the School of Medicine and School of Life Sciences, Tsinghua University, Beijing. His research spans cancer signaling pathways, extracellular vesicle-mediated communication, and stem cell therapy, especially in lung diseases and tumor biology. A seasoned scholar, Dr. Chang earned his Ph.D. in Animal Genetics and Breeding before undertaking postdoctoral training at the University of Alabama at Birmingham. He is currently a respected editor of FEBS Letters and a leader in molecular oncology in China. His recent works highlight the role of CREPT, Smad signaling, and macrophage modulation in cancer and fibrosis. Through decades of academic and translational research, he has significantly advanced our understanding of cell communication in disease contexts. With an extensive publication record in top journals, Dr. Chang remains a leading figure in Asia’s biomedical research landscape.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Pioneering Contributions in Cell Communication
    Prof. Chang’s research on CREPT, Smad proteins, NF-κB/Nrf2, and BMP signaling has directly advanced the understanding of how intracellular and intercellular communication impacts disease progression, especially in cancer and pulmonary disorders.

  2. High-Impact Publications
    He has numerous peer-reviewed articles in prestigious journals such as Nature Communications, Molecular Cancer, Signal Transduction and Targeted Therapy, and Journal of Biological Chemistry, many of which explore molecular and cellular communication in cancer and tissue repair.

  3. Translational Focus
    His integration of mesenchymal stem cell therapy, extracellular vesicles, and gene therapy reflects a strong translational approach, applying basic science to therapeutic innovations—a critical criterion for this award.

  4. Scientific Leadership and Mentorship
    As a tenured professor at Tsinghua University and editor at FEBS Letters, Prof. Chang is a leader in biomedical research and scientific dissemination, actively contributing to academic growth and mentorship.

⚠️ Areas for Improvement:

  1. More Global Recognition
    While well-known in Chinese biomedical circles and respected internationally through publications, increased involvement in global consortia or leadership in international collaborations would further solidify his global scientific footprint.

  2. Public/Community Science Engagement
    Enhancing visibility through public lectures, science communication platforms, or policy advisory roles could broaden the societal impact of his work.

  3. Data-Sharing and Open Science Practices
    Encouraging or highlighting open-access datasets, repositories, or reproducible workflows would align with best practices in modern cell communication research.

🎓 Education:

Professor Zhijie Chang began his academic journey at Northwestern Agricultural University in Yangling, China, where he earned his B.Sc. (1978–1982) in Animal Science. He then continued at the same institution to obtain a combined M.Sc. and Ph.D. in Animal Genetics and Breeding from 1982 to 1989. His graduate research laid the foundation for his future in molecular biology, signaling studies, and genetics. Seeking international exposure and advanced training, he undertook postdoctoral research from March 1997 to October 1998 at the University of Alabama at Birmingham, USA, in the Department of Pathology. There, he specialized in the BMP signaling pathway, gaining expertise in molecular signaling processes critical to cell communication. This blend of domestic and international education has equipped Dr. Chang with both the technical rigor and global perspective needed to pioneer breakthroughs in biomedical science.

💼 Professional Experience:

Professor Zhijie Chang has held a full professorship at Tsinghua University’s School of Medicine since June 2005, where he investigates cancer-related signaling mechanisms. Before this, he completed postdoctoral research at the University of Alabama at Birmingham, focusing on BMP signaling, which strengthened his understanding of developmental and pathological cell signaling. Over the years, he has built a highly productive research lab, contributed extensively to translational medicine, and trained numerous doctoral and postdoctoral researchers. As an editor of FEBS Letters, he also contributes to scientific publishing and peer-review processes. His roles across academia, research, and editorial boards mark him as a multifaceted scientist whose work bridges laboratory insights and therapeutic applications. His collaborative style and consistent research funding reflect his leadership and innovation in molecular oncology and regenerative medicine.

🏅 Awards and Honors:

Professor Zhijie Chang has been recognized multiple times by the Chinese Cell Biology Society for his high-impact publications. In 2003, he received the First Merit Paper Award for his groundbreaking research on hSef-mediated MAPK signaling inhibition in J. Biol. Chem. In 2005, he earned the Third Merit Paper Award for his study on CHIP-mediated degradation of Smad proteins, published in Mol. Cell. Biol.. These awards underscore his early and sustained contributions to deciphering molecular signaling pathways involved in cell communication, differentiation, and oncogenesis. His recent recognitions include publications in top-tier journals like Nature Communications, Molecular Cancer, and Signal Transduction and Targeted Therapy, indicating the continued relevance and innovation of his work. His role as an editor for FEBS Letters further highlights his stature in the field and dedication to advancing cell biology research at national and international levels.

🔬 Research Focus:

Dr. Zhijie Chang’s research primarily investigates cellular communication in cancer and inflammatory diseases, with a focus on CREPT, Smad proteins, and extracellular vesicles. His work dissects how tumor-derived signals modulate the tumor microenvironment, metastasis, and immune cell behavior. He has made critical discoveries regarding the role of CREPT in chromatin looping and transcriptional regulation, especially in triple-negative breast cancer. In pulmonary fibrosis models, he has shown how umbilical cord-derived mesenchymal stem cells (MSCs) modulate macrophage activity via secreted vesicles. Another major area is his exploration of Smurf1, PDK1–Akt, and JAK/STAT3 signaling axes, targeting them for therapeutic intervention in various cancers. His translational approach integrates gene therapy, stem cell-based treatments, and protein signaling studies, bridging basic and clinical sciences. Through collaborative and interdisciplinary methods, Dr. Chang contributes valuable insights into how cells communicate and respond in disease settings.

📚 Publication Top Notes:

  1. 📘 CREPT is required for the metastasis of triple-negative breast cancer through a co-operational-chromatin loop-based gene regulation

  2. 🧪 Clinical investigation on nebulized human umbilical cord MSC-derived extracellular vesicles for pulmonary fibrosis treatment

  3. 🧬 Gene Therapy with Enterovirus 3C Protease: A Promising Strategy for Various Solid Tumors

  4. 🌬 Umbilical cord-derived mesenchymal stem cells preferentially modulate macrophages to alleviate pulmonary fibrosis

  5. ⚡ CREPT upregulates the antioxidant genes via activation of NF-κB/Nrf2 in acute liver injury

  6. 🔁 An oncoprotein CREPT functions as a co-factor in MYC-driven transformation and tumor growth

  7. 🎯 Targeting Smurf1 to block PDK1–Akt signaling in KRAS-mutated colorectal cancer

  8. 📤 Microenvironment-induced CREPT expression by cancer-derived small extracellular vesicles primes field cancerization

  9. 🔋 Oxidative phosphorylation safeguards pluripotency via UDP-N-acetylglucosamine

  10. 🍄 Lachnochromonin, a fungal metabolite from Lachnum virgineum, inhibits cell growth and promotes apoptosis in tumor cells through JAK/STAT3 signaling

🧾 Conclusion:

Professor Zhijie Chang exhibits a robust and well-established career built on investigating mechanisms of cell signaling, tumor microenvironment dynamics, and intercellular communication. His scientific rigor, translational impact, and leadership in the field of cell communication make him an outstanding candidate for the Research for Cell Communication Award. Addressing some broader outreach and open science practices could further elevate his profile, but his contributions to foundational and applied research in this domain are already exemplary.

Zhi Guo | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Prof. Dr Zhi Guo | Stem Cell Research | Best Researcher Award

Prof. Dr Zhi Guo | Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital | China

Dr. Zhi Guo is a distinguished expert in hematology with over 25 years of clinical and academic experience. Currently serving as Director, Academic Leader, Chief Physician, and Professor at the Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital, he has been instrumental in advancing hematologic malignancy treatments in China. With extensive expertise in hematopoietic stem cell transplantation, Dr. Guo has successfully performed more than 1,300 transplant cases. He began his career at the PLA Army General Hospital, serving there for nearly two decades before transitioning to his current role. A prolific researcher, he has authored over 10 peer-reviewed publications and five books, contributing substantially to the understanding of CAR-T therapy, gut microbiota, and transplantation immunology. He is an active member of major national and international hematology associations and plays a vital role in formulating clinical consensus and guidelines in China.

publication profile:

Scopus

Strengths for the Award:

Dr. Zhi Guo exemplifies the qualities of an outstanding medical researcher and clinician. With nearly 25 years of clinical experience in hematology and over 20 years in hematopoietic stem cell transplantation, he stands out as a national leader in this field. His performance of more than 1,300 transplants, along with a strong academic footprint, including 10 SCI-indexed publications in 2024–2025, demonstrates both depth and innovation in his research. He has also contributed to national expert consensus and clinical guidelines, particularly in CAR-T therapy and intestinal microecology. Dr. Guo’s leadership roles across national academic committees and his active membership in the American Society of Hematology further highlight his international impact and collaborative influence.

Areas for Improvement:

While Dr. Guo’s achievements in clinical practice and research are significant, opportunities exist to increase global visibility by expanding his research collaborations internationally and publishing in higher-impact journals beyond regional scopes. Additionally, while five books have been authored, the addition of patents or translational innovations could enhance his profile in the realm of research commercialization and practical medical technologies.

Education :

Dr. Zhi Guo holds a strong academic background in clinical medicine and medical research. He earned his Bachelor’s degree in Medicine from Tongji Medical College in 2000. Subsequently, he pursued his postgraduate medical studies at the Third Military Medical University, completing it in 2007. His academic journey culminated with the attainment of a Doctor of Medicine (MD) degree from Wuhan University of Science and Technology. His education laid a strong foundation in hematology and clinical research methodologies. Each step in his educational path was marked by an emphasis on academic rigor and clinical competence, preparing him for a leadership role in medical science and hematologic research. His multidisciplinary background has enabled him to integrate clinical insights with advanced laboratory-based innovations, contributing to national-level guidelines and the development of cutting-edge CAR-T cell therapies and transplantation techniques.

Experience :

Dr. Zhi Guo brings nearly 25 years of clinical, academic, and leadership experience in the field of hematology. He began his professional journey at the PLA Army General Hospital, where he served from 2000 to 2018. During this period, he honed his clinical and procedural expertise in managing complex hematologic disorders. Since 2018, he has been leading the Department of Hematology at Huazhong University of Science and Technology Union Shenzhen Hospital as Director, Academic Leader, and Chief Physician. His rich experience includes more than 1,300 hematopoietic stem cell transplantations, encompassing autologous, allogeneic, and CAR-T integrated therapies. His leadership extends beyond clinical care, as he also mentors postgraduate medical students and leads multiple national and institutional research projects. Dr. Guo’s practical experience is balanced with his strategic contributions to medical consensus formulation and research-driven policy initiatives in cancer and immune-hematological disorders.

Research Focus :

Dr. Zhi Guo’s research centers on hematologic malignancies and hematopoietic stem cell transplantation, particularly the integration of cellular immunotherapy such as CAR-T cell treatments. His recent work includes pioneering anti-CD19, anti-CD7, and anti-BCMA CAR-T therapies for lymphomas and leukemias. Additionally, he has investigated the interplay between microbiota and immune modulation in transplantation, highlighting the role of gut and oral microbiomes in patient outcomes. His contributions have influenced the development of clinical guidelines for microbiota-related diagnostics and treatments in oncology. With more than 10 high-impact journal publications and ongoing projects in translational medicine, Dr. Guo’s work combines laboratory innovation with patient-centered applications. He has also authored expert consensus documents and national guidelines, helping shape China’s hematology and transplantation protocols. His commitment to interdisciplinary collaboration, clinical innovation, and translational research underscores his leading role in advancing modern hematology.

Publications Top Notes:

  1. 🧬 In vitro validation of anti-CD19 CAR-T cells with LSD1 shRNA for DLBCL – Front Immunol, 2025

  2. 🩸 Case of T-ALL treated with chemo + anti-CD7 CAR-T (retroviral vector) – Front Immunol, 2025

  3. 👶 Shaping oral/intestinal microbiota & immunity in first 1,000 days of life – Front Pediatr, 2025

  4. 💩 Fecal microbiota transplantation in acute GVHD treatment – J Cancer Res Ther, 2024

  5. 🔬 Chinese consensus on gut microecology lab standards – Exp Ther Med, 2024

  6. 🧪 2024 Chinese guidelines for intestinal microecology in cancer – J Cancer Res Ther, 2024

  7. 🧫 First MM case treated with ASCT + anti-BCMA CAR-T (retrovirus) – Heliyon, 2024

  8. 🧾 Rapid response in relapsed FL to anti-CD19 CAR-T with CMV – Int Immunopharmacol, 2024

  9. 🦷 Prognostic impact of oral microbiome in cancer survival – meta-analysis – Syst Rev, 2024

  10. 🧍‍⚕️ Expert consensus on gut microbiome & hematopoietic stem cell transplantation – Clin Transplant, 2024

Conclusion:

In conclusion, Dr. Zhi Guo is highly suitable for the Best Researcher Award. His combination of clinical excellence, academic leadership, and impactful research in hematology and stem cell transplantation positions him among the top contributors in this specialized field. With ongoing research in CAR-T cell therapies, microbiota influence on transplantation, and immuno-oncology, Dr. Guo continues to shape the future of hematologic cancer care. Recognizing his contributions with this award would be both fitting and encouraging for continued innovation in this vital area of medicine.

 

Basavaraj Vastrad | Gene Regulation Epigenetics | Best Researcher Award

Published on by Cell Biologist

Dr. Basavaraj Vastrad | Gene Regulation Epigenetics | Best Researcher Award

Dr. Basavaraj Vastrad, KLE College of Pharamac, Gadag, karanataka 582101, India

Dr. Basavaraj Vastrad is a distinguished Indian scientist specializing in pharmaceutical biotechnology and bioinformatics. With over 15 years of research experience, his work bridges cutting-edge genomics, next-generation sequencing (NGS), and computational biology to uncover genetic underpinnings of complex diseases like Alzheimer’s, diabetes, schizophrenia, and various cancers. He holds a Ph.D. in Biochemistry from Kuvempu University and a Master’s in Pharmaceutical Biotechnology from JSS College of Pharmacy. A prolific researcher, Dr. Vastrad has contributed to over 25 impactful publications in reputed international journals. His collaborative efforts with interdisciplinary teams have yielded novel insights and molecular targets for diseases with high clinical burden. Recognized for his methodical approach and academic excellence, Dr. Vastrad has emerged as a thought leader in bioinformatics-driven drug discovery and disease modeling. With a deep commitment to translational research, he continues to shape the scientific understanding of human health and disease.

Publication Profile: 

Google Scholar

✅ Strengths for the Award:

  1. Extensive Research Contributions
    Dr. Vastrad has published over 25 high-quality research articles, many in international, peer-reviewed, indexed journals. His work spans crucial fields including bioinformatics, genomics, neurodegenerative diseases, cardiovascular disorders, and reproductive health.

  2. Focus on Translational Research
    His research directly addresses major global health concerns—Alzheimer’s, Huntington’s, diabetes, PCOS, schizophrenia, and cardiovascular diseases—using next-generation sequencing (NGS) and computational biology. This demonstrates not only scientific depth but also clinical relevance.

  3. Strong Bioinformatics Expertise
    Dr. Vastrad applies state-of-the-art bioinformatics tools and techniques to identify novel biomarkers, therapeutic targets, and disease-related pathways, offering substantial contributions to personalized medicine and drug discovery.

  4. Solid Foundation in Biochemistry and Biotechnology
    With a Ph.D. in Biochemistry and a Master’s in Pharmaceutical Biotechnology, he brings a robust interdisciplinary background that supports a holistic approach to research problems.

  5. Experience in Microbial Biotechnology and SSF
    His earlier work on solid-state fermentation (SSF) for antibiotic production from agro-industrial waste reflects his ability to integrate sustainability with industrial biotechnology.

  6. Collaborative and Multidisciplinary Approach
    His collaborations with researchers across domains (pharmacology, genetics, medicine, and bioinformatics) showcase a team-oriented and integrative research mindset.

⚠️ Areas for Improvement:

  1. International Recognition and Grants
    While his publication record is excellent, securing global research grants, international collaborations, and patents would further enhance his global research standing.

  2. Innovation Translation
    Translating his bioinformatics discoveries into patents, prototypes, or clinical tools would significantly amplify the societal impact of his work.

  3. Leadership in Research Communities
    Serving on editorial boards, leading consortia, or contributing to scientific policy and outreach would help extend his influence in the scientific community.

🎓 Education:

Dr. Basavaraj Vastrad’s academic journey began with a Bachelor’s in Pharmacy from K.L.E’s College of Pharmacy, Hubli under RGUHS, Bangalore, completed in 2003. He pursued his Master of Pharmacy in Pharmaceutical Biotechnology from J.S.S. College of Pharmacy, Ootacamund (affiliated to The Tamil Nadu Dr. M.G.R. Medical University), which he completed in 2006. Driven by his passion for biomedical research, he earned his Ph.D. in Biochemistry from Kuvempu University, Shimoga, in 2013. His academic training is rooted in pharmaceutical sciences, molecular biology, and biotechnological applications, providing him a strong foundation in both experimental and computational research methodologies. Dr. Vastrad’s educational background reflects a harmonious blend of practical pharmaceutical knowledge and bioinformatics expertise—skills he now applies to genomics, drug discovery, and disease pathway elucidation. Each academic milestone laid the groundwork for his prolific research career focused on solving health-related challenges through innovative approaches.

👨‍🔬 Experience:

Dr. Basavaraj Vastrad has an extensive research and teaching experience spanning over a decade, primarily focusing on pharmaceutical biotechnology, solid-state fermentation, and bioinformatics. Early in his career, he specialized in microbial techniques, including antimicrobial assays and sterility testing. He later advanced to complex genomic data analysis using NGS and bioinformatics tools to decode molecular mechanisms behind various human diseases. His contributions have been instrumental in identifying biomarkers and therapeutic targets for disorders such as Alzheimer’s, schizophrenia, cardiovascular diseases, and metabolic syndromes. Collaborating with clinical and academic institutions, he has co-authored several high-impact research papers. He has also mentored junior researchers and contributed to numerous interdisciplinary studies. Dr. Vastrad’s experience in solid-state fermentation has led to optimized antibiotic production using agro-industrial waste, showcasing his ability to translate basic science into practical applications. His work stands out for its scientific rigor, innovative approaches, and potential for real-world clinical impact.

🔬 Research Focus:

Dr. Basavaraj Vastrad’s research is primarily centered around the application of bioinformatics and next-generation sequencing (NGS) to investigate the genetic and molecular basis of complex diseases. His projects have successfully decoded the signaling pathways, biomarkers, and therapeutic targets associated with conditions like Alzheimer’s disease, Huntington’s disease, PCOS, heart failure, endometriosis, schizophrenia, and various cancers. Another aspect of his research explores solid-state fermentation for the optimization of antibiotic production, using agro-industrial waste as a substrate. Dr. Vastrad applies computational tools to perform gene expression profiling, pathway enrichment, molecular docking, and biomarker identification. He also collaborates extensively with clinicians and scientists in integrating bioinformatics findings into potential translational therapies. His focus on data-driven diagnostics and personalized medicine represents a blend of computational science with tangible health outcomes. His goal is to harness bioinformatics for predictive diagnostics, therapeutic development, and a deeper understanding of pathophysiological mechanisms.

📚 Publications Top Notes:

  1. 🔍 Bioinformatics analysis of NGS data to diagnose crucial and novel genes in gestational diabetes mellitus

  2. 🧠 Identification of key genes in Huntington’s disease using NGS and bioinformatics

  3. 🧬 Analysis of Alzheimer’s disease pathways using NGS and computational approaches

  4. 🧘‍♂️ Key gene identification in schizophrenia using NGS-based bioinformatics

  5. 👩‍⚕️ Polycystic ovary syndrome: bioinformatics-based gene pathway identification

  6. ❤️ Myocardial infarction: NGS-driven bioinformatics marker analysis

  7. 👩 Endometriosis biomarkers identified using bioinformatics and NGS

  8. 🌬 Gene expression in idiopathic pulmonary fibrosis via bioinformatics and NGS

  9. 🔬 Molecular markers in pancreatic ductal adenocarcinoma using bioinformatics

  10. 💓 Heart failure: discovery of genes and pathways through NGS data

🧾 Conclusion:

Dr. Basavaraj Vastrad is highly deserving of the Best Researcher Award. His consistent contributions to bioinformatics and pharmaceutical biotechnology, innovative approaches to disease genomics, and impactful publications demonstrate scientific excellence, depth, and relevance. He not only pushes the boundaries of current biomedical knowledge but also aligns his work with pressing healthcare needs.

Sheng-Chi Hsu | molecular diagnosis | Best Researcher Award

Published on by Cell Biologist

Mrs. Sheng-Chi Hsu | molecular diagnosis | Best Researcher Award

Mrs. Sheng-Chi Hsu , Department of Laboratory Medicaine, Chang Gung Memorial Hospital at LinKou , Taiwan

Sheng-Chi Hsu, M.S., is a leading expert in tumor biology, molecular pathology, and personalized medicine. Currently serving as the Deputy Director of the Department of Laboratory Medicine at Chang Gung Memorial Hospital, Linkou Branch, he has extensive experience in cancer diagnostics, molecular pathology, and clinical research. With a strong academic background and a commitment to advancing medical science, Hsu has contributed significantly to the field of oncology, focusing on novel diagnostic approaches and precision medicine strategies. His research has resulted in several impactful publications, enhancing diagnostic accuracy and the development of targeted therapies for various cancers. Hsu’s work has played a pivotal role in improving patient outcomes and shaping the future of cancer treatment in Taiwan.

Publication Profile: 

Scopus

Strengths for the Award:

Sheng-Chi Hsu has demonstrated exceptional expertise in tumor biology, molecular pathology, and personalized medicine, contributing to groundbreaking advancements in cancer diagnostics and precision medicine. His leadership roles at Chang Gung Memorial Hospital, particularly in the Department of Laboratory Medicine and Pathology, showcase his ability to manage large teams and oversee complex laboratory operations while pushing the boundaries of research. His publications in prestigious journals highlight significant research achievements, including the identification of key biomarkers for cancer therapies and advancing molecular diagnostic techniques. Hsu’s research on cancer biomarkers, including ALK translocation and ROS1 translocation in non-small cell lung cancer (NSCLC), has provided valuable insights into targeted therapies, which are directly influencing patient care and therapeutic approaches. His work on multidrug resistance also opens new therapeutic avenues to overcome chemotherapy resistance, making his contributions pivotal to modern cancer treatment strategies.

Areas for Improvements:

While Hsu’s research accomplishments are impressive, expanding his involvement in large-scale, multi-center clinical trials could further enhance the real-world application and validation of his research findings. Collaborating with international institutions or expanding his research scope to include more diverse populations may also increase the generalizability and impact of his findings. Additionally, although Hsu has an extensive background in molecular diagnostics, there may be room to explore emerging technologies, such as artificial intelligence in pathology, to further optimize diagnostic procedures and improve precision medicine outcomes.

Experience:

Sheng-Chi Hsu has over 15 years of experience in laboratory medicine and pathology, with expertise in tumor pathology and molecular diagnostics. He is currently the Deputy Director of the Department of Laboratory Medicine at Chang Gung Memorial Hospital, where he leads research and development in laboratory diagnostics. Previously, he served as the Deputy Director of the Department of Pathology, overseeing innovations in histopathological diagnostics. Hsu’s leadership has been instrumental in advancing cancer diagnostics, optimizing molecular diagnostic techniques, and improving laboratory workflows. His career also includes roles as a Chief and Senior Medical Technologist, where he pioneered research in tumor pathology, focusing on biomarker identification and the development of diagnostic assays.

Research Focus:

Sheng-Chi Hsu’s research focuses on advancing molecular diagnostics, particularly in oncology. His work aims to enhance diagnostic precision for various cancers, with a strong emphasis on personalized medicine. Hsu has made significant contributions to the genetic characterization of tumors, identifying key biomarkers for targeted therapies in non-small cell lung cancer (NSCLC), synovial sarcoma, and gestational trophoblastic disease. His research in multidrug resistance mechanisms and the role of Wnt5A in cancer therapy has opened new avenues for overcoming chemoresistance. Hsu’s pioneering studies in molecular pathology have significantly impacted clinical practices, helping improve treatment strategies and patient outcomes through advanced diagnostics.

Publications Top Notes:

  1. Wang HS, Liu CY, Hsu SC, Huang SC, Hung TH, Ng KF, Chen TC. A Single-Institute Experience with C-ros Oncogene 1 Translocation in Non-Small Cell Lung Cancers in Taiwan. Int J Mol Sci. 2022 May 21;23(10):5789. 📄
  2. Hsu SC, Hung TH, Wang CW, Ng KF, Chen TC. Anaplastic lymphoma kinase translocation is correlated with anaplastic lymphoma kinase expression and mutually exclusive with epidermal growth factor receptor mutation in Taiwanese non-small cell lung cancer. Pathol Int. 2015 May;65(5):231-9. 📄
  3. Hung TH, Hsu SC, Cheng CY, Choo KB, Tseng CP, Chen TC, Lan YW, Huang TT, Lai HC, Chen CM, Chong KY. Wnt5A regulates ABCB1 expression in multidrug-resistant cancer cells through activation of the non-canonical PKA/β-catenin pathway. Oncotarget. 2014 Dec 15;5(23):12273-90. 📄
  4. Chen KH, Hsu SC, Chen HY, Ng KF, Chen TC. Utility of fluorescence in situ hybridization for ploidy and p57 immunostaining in discriminating hydatidiform moles. Biochem Biophys Res Commun. 2014 Apr 4;446(2):555-60. 📄
  5. Chuang HC, Hsu SC, Huang CG, Hsueh S, Ng KF, Chen TC. Reappraisal of TLE-1 immunohistochemical staining and molecular detection of SS18-SSX fusion transcripts for synovial sarcoma. Pathol Int. 2013 Dec;63(12):573-80. 📄

Conclusion:

Sheng-Chi Hsu is highly deserving of the “Best Researcher Award” due to his outstanding contributions to cancer research and diagnostic advancements. His innovative approach to tumor pathology and molecular diagnostics, along with his leadership in clinical and research operations, makes him a transformative figure in the field. With a continued focus on expanding his research scope and incorporating emerging technologies, Hsu’s impact on personalized cancer treatments is poised to grow even further.